Mentari Therapeutics Secures \$200 Million Private Placement Ahead of InMed Merger: Major Milestone in Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 – In a significant development for the biotech and healthcare investment community, Mentari Therapeutics, Inc., a privately-held biotechnology company focused on migraine prevention therapies, announced the closing of a \$200 million private placement. This transaction, involving prominent institutional healthcare investors, comes just before Mentari’s planned merger with InMed Pharmaceuticals, Inc. (Nasdaq: INM), setting the stage for the emergence of a new, well-capitalized player in the neurological therapeutics sector.
Key Points of the Report
- Private Placement Details: Mentari secured \$200 million through a private placement consisting of common stock and pre-funded warrants to purchase common stock. The placement features participation from a consortium of leading healthcare investors, including Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deepck Capital, Vivo Capital, Commodore Capital, BB Biotech, and others.
- Investor Syndicate: The caliber and breadth of the investor base in this round underscores robust confidence in Mentari’s science and business prospects.
- Financial Extension: The fresh capital, combined with existing resources, is expected to extend Mentari’s cash runway into 2029, allowing the company to advance its two lead PACAP-targeted programs – including MT-002 – through key clinical milestones and readouts. It also supports the broader development of the company’s migraine prevention pipeline.
- Merger and Trading Update: The private placement is structured to close immediately prior to the completion of Mentari’s merger with InMed Pharmaceuticals. Upon closing, the combined entity will continue under the Mentari Therapeutics name and will trade on the Nasdaq Capital Market under a new ticker symbol.
- Capital Structure: After completion of the merger, the new private placement, and a previously announced \$290 million placement, the combined company is expected to have approximately 601.2 million shares of common stock outstanding (on an as-converted/as-exercised basis).
- Placement Agents: Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as placement agents in the transaction.
Strategic and Pipeline Updates
- Pipeline Focus: Mentari is developing therapies to prevent migraines, aiming to address the high unmet need in a condition affecting over 1 billion people worldwide.
- Scientific Leadership: The company’s lead programs target PACAP, a recently validated mechanism distinct from CGRP, which has already demonstrated clinical and commercial success.
- Key Programs:
- MT-001: An anti-PACAP monoclonal antibody, optimized for convenient subcutaneous dosing.
- MT-002: A bispecific antibody that targets both CGRP and PACAP, designed to help patients who have an incomplete response to existing CGRP-targeted therapies, potentially offering superior outcomes.
- Discovery Engine: The pipeline was discovered by Paragon Therapeutics, supporting a robust scientific foundation.
Shareholder-Impacting and Price-Sensitive Information
- Mega Funding Event: The \$200 million placement (in addition to the prior \$290 million) significantly bolsters the balance sheet, reducing financial risks, and enabling the advancement of multiple late-stage clinical programs. This financial strength is likely to be seen positively by both existing and prospective investors.
- Merger Completion: The private placement is conditional upon, and will close alongside, the merger with InMed. If the merger or the financing does not close as planned, it could have a material impact on the company’s future direction and value.
- Combined Entity and Nasdaq Listing: The merged company will continue as Mentari Therapeutics and retain a Nasdaq listing, providing liquidity and visibility for shareholders.
- Share Count Expansion: Post-merger, the expanded share base (~601 million shares) will be a key metric for valuation and dilution analysis for investors.
- Pipeline Milestones: The newly extended cash runway into 2029 should allow Mentari to achieve critical clinical readouts for its lead programs, which could be significant catalysts for share price movement.
Regulatory and Transactional Considerations
- The merger is subject to both InMed shareholder and Mentari stockholder approvals, as well as regulatory and closing conditions (including the effectiveness of the SEC registration statement).
- There are inherent risks, including the possibility that the merger or financing may not be completed, or that Nasdaq listing or redomiciling requirements could present challenges.
- Details regarding the transaction, including proxy materials and the registration statement on Form S-4, are available for review by investors on the SEC, SEDAR+, and company websites.
Contact Information
For media inquiries:
Lia Dangelico
Deerfield Group
[email protected]
40-303-0180
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should review all regulatory filings and consult their financial advisors before making any investment decisions. Forward-looking statements in this article are subject to risks and uncertainties, and actual results may differ materially.
